Adenoviral gene transfer of immunmodulatory molecules has been employed successfully in tumor vaccination studies to induce rejection of transplanted syngeneic tumors. In contrast, the response observed when treating chemically induced murine tumors is rather limited. The same applies for human malignancies. A number of reasons including poor transduction efficiency or insufficient T cell infiltration have been held accountable for this lack of efficacy. However, little attention has been given to effects of the adenoviral transduction itself on the T cell system. Here, we show that T cells are sensitized for activation-induced cell death after co-culture with adenovirally infected tumor cells. The levels of CD95/Fas ligand or TNF-␣, both known mediators
Introduction
Although capable of presenting MHC class I restricted antigens, 1 tumor cells generally fail to initiate an effective tumor directed T cell response. 2 In contrast, genetic engineering of tumor cells by the use of costimulatory molecules or cytokines facilitates tumor rejection and fosters an efficient immune response towards tumor rechallenge with non-engineered tumor cells in various tumor models.
Recent data have shown that transgene selection and delivery is crucial for tumor immunotherapy. [3] [4] [5] Due to multiple advantages, eg high efficacy of in vivo transfection, ability to transduce non-dividing cells, lack of oncogenicity and low pathogenicity, replication-deficient adenoviral vectors are used as vehicles for transgene expression in a number of clinical trials and experimental in vivo models. 6 While replication-deficient adenoviral vectors have been described to induce a number of molecular changes in infected cells, little is known about their impact on non-transduced bystander cells. [7] [8] [9] This holds true especially for the T cells which are often the target of
of activation induced cell death, however were not affected by the presence of adenovirus-infected target cells. Furthermore, supernatant transfer from adenovirally transduced or non-infected tumor cell cultures did not result in increased T cell apoptosis. This suggests that cell contact rather than a soluble factor is responsible for the induction of T cell apoptosis upon co-culture with adenovirally transduced tumor cells. Interestingly, and in line with our previous observations, activation-induced cell death was partially inhibited if T cells were co-cultured with tumor cells adenovirally transduced to express IL-7 and CD80, both molecules having the capacity to prevent T cell apoptosis.
Gene Therapy (2002) 9, 1438-1446. doi:10.1038/sj.gt.3301796 vaccination studies. In the presented work, we show that co-culture between adenovirally infected cells and T lymphocytes results in increased activation-induced cell death (AICD).
Interestingly, the increase of AICD was partially overcome when T cells were co-cultured with tumor cells adenovirally infected to express IL-7 and CD80, both molecules being capable of inhibiting AICD. The finding of increased apoptosis susceptibility in co-cultured T cells upon adenoviral transduction of carcinoma cells might help to explain the so far limited success of tumor vaccination studies based on adenoviral gene transfer.
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Results
Alloreactive T cell cyctotoxicity is not affected by coculture with adenovirally transduced tumor cells
To assess the effects of adenoviral transduction of tumor cells on co-cultured, non-infected T lymphocytes, lethally irradiated SAOS-2 osteosarcoma cells were co-incubated with PBMCs from healthy donors at a final concentration of 1 × 10 6 /ml. Cultures were performed with tumor cells at a final concentration of 1 × 10 5 /ml, either non-transduced or adenovirally infected with Ad-lacZ at increasing multiplicity of infection (MOI). Before irradiation and co-culture, the efficacy of adenoviral infection was determined by X-gal staining. Almost all infected tumor cells were positive for ␤-gal at MOI of 50 or 100 and, as expected, no signs of apoptosis could be observed in infected cells (data not shown).
After 6 days of co-incubation, non-adherent cells were harvested and analyzed for CD3 surface expression to assess the portion of T lymphocytes. Non-adherent cells harvested from PBMC initially stimulated with SAOS-2 or SAOS-2-Ad-lacZ cells were 93 ± 1.2% and 92 ± 0.3% CD3 positive. No differences regarding CD4 and CD8 positivity and surface expression were detected (data not shown). To determine whether co-culture with adenovirally infected tumor cells had an effect on T cell effector function, as compared with PBMC cultured with noninfected SAOS-2 cells, cytotoxicity was measured. This was done by co-incubating 51 Cr-labeled, non-infected SAOS-2 tumor target cells with prestimulated T cells at various effector-target (E:T) ratios. After 4 h of co-culture, cytotoxic T cell activity was assessed by measuring 51 Cr release from lysed tumor cells. T cells displayed similar cytotoxicity towards uninfected tumor cells regardless of prior stimulation with SAOS-2 tumor cells infected with Ad-lacZ at a MOI of 100 or with non-transduced tumor cells ( Figure 1 ). To further ensure that the observed tumor cell lysis was executed by T lymphocytes and not by NK cells, cytotoxicity assays were performed with T cells purified by depletion of CD11b, CD14, CD19 and CD16 positive cells. Cells were more than 95% positive for CD3 while being negative for CD56 or CD14. As expected, these purified T cells were capable of lysing SAOS-2 tumor cells and no difference was detectable between T cells initially activated by non-infected or AdlacZ-transduced tumor cells (data not shown). Co-culturing T cells with adenovirally transduced renal cancer cells (RCC26) yielded similar results (data not shown). Thus, T cell effector function upon restimulation was not altered by the adenoviral transduction of the type of stimulator cells in the primary culture.
Figure 1 Cytotoxic T lymphocyte mediated tumor cell lysis during restimulation with non-infected SAOS-2 osteosarcoma cells. T lymphocytes stimulated primarily with non-infected SAOS-2 cells (open circles)
or Ad-lacZ-infected SAOS-2 cells (MOI 100) (filled squares) were restimulated after 6 days of culture through co-culture with 51 Cr bearing, non-infected SAOS-2 cells at the indicated effector-target ratios. After 4 h of co-culture, 51 Cr release from lysed SAOS-2 cells was measured. A representative result from three independent experiments is shown.
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Adenovirally transduced tumor cells increase activation induced cell death of non-infected T lymphocytes
Interestingly, during the experiments described above, we observed that a significantly higher percentage of T cells underwent activation-induced cell death (AICD) 18 h after restimulation with non-infected tumor cells when the initial stimulation was performed by the use of adenovirally transduced tumor cells (P = 0.018). The amount of T cell apoptosis was compared with T cells activated by non-infected SAOS-2 cells on both occasions (primary activation and restimulation) or T cells initially cultured in complete medium and IL-2 and restimulated with noninfected SAOS-2 cells. Restimulation of the T cells at day 6 by the use of the uninfected SAOS-2 cells resulted in 40 ± 11.2% apoptosis when the primary activation at day 0 was done with adenovirally transduced SAOS-2, as compared with 26 ± 4.6% when uninfected SAOS-2 were employed and 20 ± 4.5% when the T cells were cultured in IL-2 alone (Figure 2a) . Next, to assess whether adenovirally induced AICD increase is MOI-dependent, we cultured T cells during the initial stimulation with AdlacZ-infected tumor cells transduced at MOIs of 1, 50 and 100. Here, apoptosis augmented MOI dependent, rising from a mean of 29 ± 1.9% at a MOI of 1 to a mean of 46 ± 11.0% at a MOI of 100 (Figure 2b ). To further ensure that the observed increase of AICD resulted from T cell apoptosis, negatively isolated T cells (98% CD3 positive) were employed during the primary activation in the coculture with non-infected or adenovirally transduced SAOS-2 cells, leading to 18% and 35% AICD, respectively. When assessing the ratio of CD4 to CD8 T cells before and after restimulation, ratios remained unchanged indicating that AICD does not occur preferentially in CD4-positive or in CD8-positive T lymphocytes (data not shown). Furthermore, when measuring apoptosis on day 6 of the co-culture, directly before restimulation, similar values of T cell apoptosis were obtained irrespective of whether T cells had been initially stimulated with non-infected or Ad-lacZ-transduced tumor cells (data not shown). Thus, adenoviral transduction of the stimulator cells in the primary stimulation does not appear to influence T cell apoptosis during the primary stimulation.
To rule out that adenoviral transduction of T cells by adenovirus during co-culture with infected malignant cells was responsible for T lymphocyte death, PBMC and irradiated SAOS-2 cells, the latter infected with Ad-lacZ at a MOI of 100 before the co-culture, were co-cultured for 3 days. Subsequently, non-adherent cells were harvested and X-gal expression was measured either in PBMC or cells enriched for CD4 and CD8 expression by positive selection with immunomagnetic beads. As expected, neither PBMC nor the subfractionated T cells were infected by Ad-lacZ, as detected by X-gal staining (data not shown). Co-culture of PBMC with Ad-lacZinfected RCC26 renal carcinoma cells induced similar percentages of apoptosis and T cells were not infected by adenovirus (data not shown).
T cell apoptosis is not mediated by increased levels of soluble CD95 ligand or TNF-␣
To assess whether a soluble factor is involved in the observed effect, we harvested supernatants from 18 h cocultures of non-infected SAOS-2 cells and T cells prestimulated either with Ad-lacZ-or non-infected tumor 
Subsequently, T cell apoptosis was detected by measuring Annexin-V-FITC-staining. Mean values and standard deviations from data of seven independent experiments are depicted. (b) Apoptosis was increased MOI dependent. T lymphocytes were primarily activated by coculture with non-infected SAOS-2 cells or SAOS-2 cells transduced with Ad-lacZ at a MOI of 1, 50 or 100. After 6 days of co-culture T lymphocytes from all conditions were restimulated with non-infected tumor cells. Mean values and standard deviations from three independent experiments are depicted.
cells. Our previous experience showed that the CD95 ligand is produced by the T cells in such co-culture systems. 13 CD95-mediated signals are inducers of activation induced death (AICD) in T cells. CD95 ligand was shown previously to be cleaved proteolytically from the membrane.
14 This soluble CD95 ligand activity was previously shown to mediate both autocrine suicide and paracrine fratricide of T cells. 13, 15, 16 To this end, levels of soluble CD95 ligand were assessed by ELISA (sCD95L). CD95L was readily detectable in the culture supernatant upon restimulation. Nevertheless, no change of sCD95L levels were present when different modes of primary cultivation were compared ( Figure 3 ). In addition, T cells initially stimulated in the absence or presence of adenovirally infected cells expressed similar levels of CD95 and were equally susceptible to CD95-mediated apoptosis induced by agonistic anti-CD95 antibodies (data not shown). Besides CD95 ligand, TNF-␣ is an important mediator of T lymphocyte apoptosis. 17 When comparing levels of TNF-␣ during reactivation of T cells initially stimulated with non-infected SAOS-2 cells or SAOS-2-Ad-lacZ cells, we detected similar amounts of TNF-␣ in supernatants from either condition, ie 22 ± 14 pg/ml and 33 ± 20 pg/ml, respectively. Thus, adenovirally induced apoptosis does not appear to be mediated by soluble CD95 ligand or TNF-␣ both key mediators of antigen driven T lymphocyte death.
Supernatants from adenovirally transduced tumor cells do not mediate AICD
To further investigate the role of soluble factors during adenovirally induced AICD, we tested whether supernatants directly harvested from adenovirally infected cells are capable of inducing apoptosis upon primary or secondary activation of T cells. To this end, PBMC were stimulated by CD3 crosslinking and cultured in complete medium alone or in complete medium containing 50% supernatant from non-infected or Ad-lacZ-infected SAOS-2 cells (MOI 100) collected 3 days after adenoviral
Figure 3 Detection of soluble CD95 ligand secretion after restimulation with non-transduced tumor cells. PBMC were primarily co-cultured either with non-infected SAOS-2 cells or Ad-lacZ-infected SAOS-2 cells (MOI 100) over a period of 6 days. Subsequently, T lymphocytes were restimulated with non-transduced tumor cells and soluble CD95 ligand secretion was measured from supernatants after 18 h of co-culture. Mean values and standard deviations from data of three independent experiments are shown.
transfection. Alternatively, supernatant from noninfected or Ad-lacZ-infected SAOS-2 cells (MOI 100) was added upon restimulation of PBMC by CD3 crosslinking. Apoptosis was detected by measuring Annexin-V-FITC positivity 18 h after primary stimulation or restimulation. SAOS-2 supernatants slightly increased T cell AICD during primary (Figure 4a ), but not during secondary stimulation (Figure 4b ). There was, however, no significant difference between the supernatants derived from the noninfected control cultures and Ad-LacZ transduced SAOS-2 cells. Thus, similar amounts of apoptosis were detected regardless of whether cells were cultured in medium containing supernatant from non-infected or Ad-lacZinfected tumor cells during primary activation (35 ± 8% vs 41 ± 8% apoptotic T cells; Figure 4a ) and whether cell death was induced upon secondary stimulation by CD3 crosslinking (51 ± 14% vs 60 ± 19% apoptotic T cells; Figure 4b) , respectively. Consequently, these differences in apoptosis did not reach a level of significance (P > 0.05).
Primary stimulation with tumor cells adenovirally transduced to express IL-7 and CD80 improves T cell cytotoxicity but only partially inhibits activation induced cell death
Signals mediated through CD80, a ligand of the T cell costimulatory molecule CD28, or through IL-7, a T cell growth factor, have been implicated in T cell proliferation and inhibition of AICD. To prevent T cell apoptosis induced by adenovirally transduced tumor cells, we generated an E1-and partially E3-deleted adenoviral vector expressing IL-7 and CD80 as transgenes under the control of a CMV promoter. Previous data in syngeneic tumor vaccination models showed an efficient vaccination effect when both IL-7 and CD80 were stably expressed on the tumor cells. 4 In addition, we previously observed a reduction of T cell AICD when CD80 was stably expressed on tumor cells. 13 Efficient CD80 surface expression and IL-7 secretion was detected by FACS analysis and ELISA, respectively, upon adenoviral transduction of SAOS-2 cells. Nearly complete expression of CD80 was achieved at a MOI of 50 (Figure 5a ). IL-7 secretion ranged from a mean of 0.01 ng/ml (MOI 1) to 55 ng/ml (MOI 100) (Figure 5b ). Neither non-infected nor Ad-lacZ transduced tumor cells expressed detectable cell surface CD80 (Figure 5a ) or secreted IL-7 (Figure 5b ).
To test whether the transgenes IL-7 and CD80 prevent T cell apoptosis, as previously observed, 13, 18 T lymphocytes were stimulated with Ad-IL-7/CD80-transduced tumor cells during the primary activation. Co-culture with Ad-LacZ-transduced SAOS-2 cells induced a significantly higher rate of T cell AICD (P = 0.028, Figure 6 ). Interestingly, culturing T lymphocytes with Ad-IL-7/CD80-transduced SAOS-2 cells resulted in decreased AICD as compared with cultures with Ad-lacZ-transduced SAOS-2 cells. This effect did, however, not reach statistical significance (P = 0.173; Figure 6 ). Nevertheless, AICD was decreased to a level not significantly different from the control cultures with non-infected SAOS-2 (P = 0.116).
Next, T lymphocyte effector function, ie cytotoxicity, was assessed. Since 51 Cr release is determined in a 4-h short-term culture, in vitro cytotoxicity is not impaired by T cell AICD which occurs later upon activation. T lymphocytes primarily stimulated with Ad-IL-7/CD80 transGene Therapy 
Discussion
While the direct effects of adenoviral infection have been examined to some extent, little is known about the impact on co-cultured, non-infected immune cells. Here, we show that adenoviral infection of tumor cells increases the susceptiblity of co-cultured, non-infected T lymphocytes to activation-induced cell death (AICD). We could rule out elevated levels of TNF-␣, soluble CD95 ligand, membrane bound CD95 receptor or increased susceptibility to CD95-mediated apoptosis as explanations for the presented results. In addition, supernatant transfer experiments demonstrated that soluble factors are not the cause of increased T cell AICD. In turn, this indicates that cell contact is required for the induction of T cell AICD in this setting. Furthermore, we show that the adenovirally mediated expression of IL-7/CD80 could partially suppress adenovirally triggered AICD susceptibility. Finally, adenoviral infection of T cells as an explanation for increased AICD was ruled out.
The data presented may help to understand the limited success when employing adenoviral vehicles to treat tumors. Such limitations are apparent in experimental therapy based on gene transfer of co-stimulatory molecules into murine tumors induced in vivo by chemical carcinogenesis and into human tumors. [10] [11] [12] 19, 20 While limited in vivo transduction efficiency or insufficient T cell infiltration have been mainly held accountable for this lack of response, little attention has been given to effects caused by the adenoviral infection itself.
Most adenoviral vectors currently employed in research and clinical trials are replication deficient. Replication incompetence is achieved by deleting the adenoviral E1 region. Nevertheless, and in contrast to earlier expectations, E1-deficient, replication-incompetent adenoviral constructs still facilitate the activation of early and late adenoviral genes, induce transcription factors like NF-B and the subsequent generation of numerous cytokines and chemokines with the capacity to influence noninfected cells. [7] [8] [9] [21] [22] [23] Supporting the data presented here, a recent publication showed that dendritic cells infected with an E1-and E3-deleted adenovirus had increased T cell stimulatory capacity at T cell/DC ratios between 200 to 1 and 40 to 1, but showed a decrease of this capacity at T cell/DC ratios of 20 to 1 and 10 to 1. 7 While the increase of the stimulatory capacity was explained with an adenovirally induced up-regulation of costimulatory surface molecules and cytokines in dendritic cells, the decrease of this capacity at lower T cell/dendritic cell ratios was not explained. 7 Keeping in mind that in our system T cells were co-cultured with tumor cells and not with dendritic cells, it is nevertheless notable that in our system apoptosis was measured in T cells that had been co-cultured with stimulating tumor cells at a ratio of 10 to 1, hence at a ratio where Morelli et al 7 observed a decrease of the stimulatory capacity of their dendritic cells.
Furthermore, the capacity of adenoviral vectors presented here, is interesting as it may explain the recent report about the limited immune response following the adenoviral transduction of chemically induced syngenic murine tumors. There, the authors observed a persistent Gene Therapy ␤-gal expression after the injection of a LacZ-encoding, E1-and partially E3-deleted adenoviral vector into solid, 3-methycholanthrene induced murine tumors. 20 Even more surprisingly, an increase of ␤-gal expression was detected after repeated adenoviral injections in spite of the fact that these animals were immuno-competent. The sustained ␤-gal expression was explained by a lack of infiltration of ␤-gal-specific T cells into the chemically induced tumors. Alternatively, the observation of a persistent ␤-gal expression would be in line with the induction of tolerance against adenovirally transduced cells, eg mediated by T cell deletion. The in vitro data presented here could explain how a pro-apoptotic factor induced in adenovirally infected cells might overrule the immune stimulatory impact of these vehicles in the abovedescribed systems.
Our data on T cell AICD induced by adenovirally infected target cells are based on the use of alloreactive T cells. It is difficult to estimate whether autologous tumorreactive T cells which occur at much lower frequencies and presumably have low affinity T cell receptors will be equally affected by adenovirally induced AICD. Nevertheless, transducing tumor cells to express costimulatory molecules or cytokines is aimed at generating and expanding high affinity, tumor-specific T cells. This, in turn, might be counteracted by adenovirally induced apoptosis.
In this line, our data might help to explain a recent observation where tumors of advanced stage cancer patients were transduced in vivo with a replicationdeficient adenoviral vector encoding human full-length wild type (wt) p53, a universal tumor-associated antigen. T cells against p53 most likely constitute low affinity Tlymphocytes which exist at low precursor frequencies as mentioned above. Interestingly, the authors neither detected the generation of cytotoxic T lymphocytes specific for wt p53 epitopes nor a reduction of tumor size subsequent to tumor transduction. A general immune deficiency was ruled out in these patients. 12 Thus, our findings may help to explain the failure to induce a T cell expansion against the adenovirally encoded antigen.
The phenomenon of apoptosis of non-infected, bystander T lymphocytes co-cultured with virally infected cells has been also described for HIV-1. There, soluble HIV-Tat, a HIV-1 genome encoded protein, is capable of promoting apoptosis of co-cultured, uninfected T lymphocytes through the interaction with the cell surface receptors CD26 and ␣5 ␤ 1 and by sensitizing non-infected cells to CD95-mediated apoptosis. 24 Similar data have been obtained for the HTLV-1 protein Tax which also sensitizes T cells for T cell receptor and CD95-triggered apoptosis. 25 In contrast to previous findings in AICD, we could not see the induction of CD95 ligand or membrane bound CD95.
Finally, when employing an adenoviral vector expressing CD80 and IL-7 as transgenes, T cell cytotoxicity upon restimulation was strongly augmented, most likely reflecting an efficient expansion of tumor cell-reactive T lymphocytes during the primary stimulation induced by an effective IL-7-and CD80-mediated costimulation. Besides functioning as a costimulatory molecule, CD80 or stimulation by its ligand, CD28, is capable of rescuing T lymphocytes from AICD, 13, 15, 26, 27 while IL-7 is critical for the survival of CD8-positive T cells and for the generation of memory cells. 28 Thus, we were anticipating that the expression of IL-7/CD80 on tumor cells would abolish pro-apoptotic signals derived from adenoviral genes. In fact, AICD was less pronounced and T cells primarily stimulated with Ad-IL-7/CD80-infected tumor cells could be partially protected from AICD. Nevertheless, this protection was incomplete, arguing that even efficient expression of anti-apoptotic ligands on tumor cells is not capable of completely antagonizing the proapoptotic adenoviral effects.
In conclusion, our data suggest that adenoviral infection of tumor cells is capable of inducing apoptosis of cocultured T cells. This adenovirally mediated T cell death may impair therapies aimed at targeting the cellular immune system against cancer cells and thereby may contribute to phenomena such as insufficient tumor infiltration by tumor reactive T lymphocytes. On the other hand, this mechanism might be exploited therapeutically to enhance sustained gene expression in vivo.
Materials and methods
Construction and preparation of recombinant replication deficient adenovirus
A replication deficient, E1-deleted and partially E3-deleted (lacking a 14 kDa protein) adenovirus expressing LacZ as a transgene (Ad-lacZ) under the control of a CMV-promoter (kind gift of R Crystal, Cornell University, New York, NY, USA) has been described elsewhere. 29 The CMV-promoter driven expression cassette facilitating the co-expression of human IL-7 and human CD80 genes was constructed using the adenovirus shuttle plasmid pHVad1 (kindly provided by the late M Strauss, Max Delbrü ck Center for Molecular Medicine, Berlin, Germany). Briefly, cDNA was generated from RNA of the human B cell lymphoma line WEWAKE II. Next, human CD80 was amplified by primers incorporating a ClaI site at the 5' end and a XhoI site at the 3' end. Subsequently, the PCR-amplified CD80 fragment was digested with ClaI and XhoI and cloned behind the poliovirus internal ribosome entry site (IRES) of the ClaI/XhoI cleaved plasmid pPBS-IRES. The resulting plasmid pIRES/CD80 was cut with XbaI and XhoI to recover the IRES/CD80 fragment. Subsequently, the XbaI and XhoI ends were blunt-ended with a Pfu PCR polishing kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's protocol. The resulting fragment was cloned blunt end into the plasmid pcDNA3 (Invitrogen, SanDiego, CA, USA) at EcoRV, thus creating the plasmid pcDNA3-IRES/CD80. Next, human IL-7 cDNA was recovered as an EcoRI fragment from plasmid pLXSN-hIL-7 30 and was inserted into the EcoRI site of pcDNA3-IRES/CD80. The resulting plasmid, pcDNA3-IL-7/IRES/CD80 was digested with NruI and NaeI. Subsequently, the expression cassette containing the CMV promoter, IL-7/IRES/CD80 and the BGHpolyA site was ligated blunt end into the EcoRV position of the multicloning site of the transfer plasmid pHVad2 (kindly provided by M Strauss). The pHVad2 System consists of a bacterial plasmid and a subsegment of the viral Ad5 genome with a deletion in the E1 region. After expansion of the transfer plasmid in E. coli bacteria, the Ad5 adenoviral subsegment was removed through a digest with PacI and StuI. The resulting fragment was recombined with the linearized Ad5 helper plasmid pHVad1 using the recBC system. 31 pHVad1 contains the complete Ad5 adenovirus genome linked to a bacterial plasmid suitable for replication in E. coli. Homologous recombination between pHVad2 and pHVad1 facilitates the insertion of foreign genes into the E1 region of the Ad5. By deleting the E1 gene, replication deficient adenoviruses were generated. Next, the recombinant adenoviral genome was released from the helper plasmid through digest with PacI. Following this, HEK 293 cells (DSMZ, Braunschweig, Germany) were transfected using a CaPO 4 transfection kit (Mammalian Transfection Kit; Stratagene, Heidelberg, Germany). Finally, the amplified adenovirus Ad-IL-7/IRES/CD80 was processed through a caesiumchloride gradient for purification. Absence of gene mutations were further confirmed by sequencing the human transgenes IL-7 and human CD80 with appropriate primers. For both adenoviral vectors, particle number was estimated by determining the amount of viral DNA by measuring optical density at 260 nm. Plaque-forming units were determined by performing a standard plaque assay.
Adenoviral gene transfer
For in vitro transfection of tumor cell lines, 1 × 10 5 tumor cells per 3-cm dish were cultured for 24 h until 75% confluency. Subsequently, cells were washed twice with Dulbecco's PBS (D-PBS) (GibcoBRL, Life Technologies, Karlsruhe, Germany). Following this, adenovirus (AdlacZ or Ad-IL-7/IRES/CD80) in 400 l of D-PBS was added at MOI as indicated and cells were incubated for 30 min on a shaker. Next, RPMI 1640 supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, 4 mM Lglutamine, and 10% fetal calf serum (GibcoBRL, Life Technologies), further depicted as complete medium, was added and cells were cultured for a total of 3 days before being used in co-culture experiments. To assess Ad-lacZ transduction efficiency, cells were analysed for ␤-gal expression with X-gal (Sigma-Aldrich, Taufkirchen, Germany). Briefly, cells were fixed in PBS supplemented with 1.0% formaldehyde, 0.2% glutaraldehyde, washed and incubated with X-gal-dye (PBS supplemented with 1 mg/ml X-gal in dimethylformamide, 4 mM K 3 Fe(CN) 6 , 4 mM K 4 Fe(CN) 6 -3H 2 O, 2 mM MgCl 2 , pH 7.4) at 37°C for 24 h, washed and assessed with an inverted microscope. Alternatively, cell lines were infected with a replication deficient adenovirus expressing IL-7 and CD80.
Transgene detection
For transgene expression, cells were incubated with a PElabeled mouse anti-human CD80 antibody (BD PharMingen, Heidelberg, Germany). Surface expression of CD80 was determined by flow cytometry on a FACScan (Becton Dickinson). Secreted IL-7 was measured using an ELISA kit (Bender MedSystems, Vienna, Austria) and an ELISA reader (SLT Labinstruments, Crailsheim, Germany). Briefly, supernatants were harvested 3 days after the transduction with the indicated adenoviral vector. Subsequently, 100 l of supernatant from each sample in duplicate was added to 100 l of standard diluent into a 96-well plate coated with an anti-IL-7 antibody. Next, 50 l biotin-conjugated anti-IL-7 antibody was added to each sample and plates were incubated at room temperature for 2 h. After washing wells three times with wash buffer, 100 l of Streptavidin-HRP (horseradish peroxidase) were pipetted into each well, and plates were incubated at room temperature for 30 min. Next, after washing wells three times with wash buffer, 100 l of TMB (tetramethyl-benzidine and hydrogen peroxide) substrate solution were added, followed by an incubation period of 20 min at room temperature. Finally, 100 l of stop solution was added and samples were measured with an an ELISA reader at 450 and 620 nm.
For assessment of PBMC or T cell transduction by AdlacZ during co-culture with adenovirally transduced cells, PBMC were incubated with Ad-lacZ infected (MOI 100), irradiated (80 Gy) SAOS-2 cells. After 3 days of coculture, non-adherent cells were harvested, washed, spun on to a microscope slide with a cytocentrifuge at 750 r.p.m. for 3 min and stained with X-gal as described above. Alternatively, non-adherent cells were enriched for CD4 and CD8 positive cells by positive isolation employing CD4 and CD8 specific antibodies conjugated to magnetic beads (Dynal, Oslo, Norway) according to the manufacturers' protocol.
Cell lines and T cell activation
The SAOS-2 osteosarcoma cell line was obtained from the German tissue bank (DSMZ, Braunschweig, Germany). RCC26, a renal cell carcinoma cell line was a kind gift from D Schendel (Maximilians University Munich, Germany). 32, 33 Peripheral blood mononuclear cells (PBMC) were obtained from whole blood of healthy donors by Ficoll separation. During the primary stimulation, PBMC were kept at a final concentration of 1 × 10 6 /ml and were co-cultivated with lethally irradiated (80 Gy) non-infected, Ad-lacZ-infected or Ad-IL-7/IRES/CD80 transduced tumor cells at a final concentration of 1 × 10 5 /ml. Alternatively, PBMC were kept in complete medium only without co-culturing tumor cells. Following 18 h of culture, recombinant IL-2 (30 U/ml) was added to all conditions. After a total of 6 days in culture, PBMC were harvested and the percentage of T cells was measured by FACS analysis of CD3, CD4 and CD8 surface expression. Next, these pre-activated T cells (1 × 10 6 /ml) were restimulated without IL-2 with noninfected tumor cells from the same tumor cell line employed during the primary stimulation (SAOS-2 or RCC26) (1 × 10 5 /ml). IL-2 was omitted from the cultures upon restimulation, since IL-2 was reported by Lenardo's group 17 to have pro-apoptotic properties, ie to trigger 'propriocidal' apoptosis. Lack of IL-2 did not affect spontaneous apoptosis of T cells during these measurements. While T cells had been initially stimulated with adenovirally transduced or non-infected tumor cells, as indicated, all T cells, even the ones that had been cultured in medium plus IL-2 alone, were restimulated with noninfected tumor cells. Alternatively, instead of employing PBMC during the primary stimulation, T cells were enriched by negative depletion through incubation with antibodies to CD11b (mouse IgG1), CD14 (mouse IgG2a), CD16 (mouse IgG1) and CD19 (mouse IgG1) (BD Biosciences, San Jose, CA, USA) followed by magnetic beadsconjugated anti-mouse antibody (pan mouse Ig Dynabeads; Dynal, Oslo, Norway) according to the manufacturer's protocol. Subsequently, T cells were used instead of PBMC as described above.
Measurement of T cell apoptosis
For assessment of T lymphocyte apoptosis, pre-activated T cells were restimulated with irradiated, non-infected Gene Therapy tumor cells for 18 h. Subsequently, apoptosis was detected by FACS analysis of Annexin-V-FITC (PharMingen, San Diego, CA, USA) binding to membrane phospholipid phosphatidyl serine on the outer leaflet of the plasma membrane. As a control, apoptosis was measured before restimulation. For measurement of CD95 ligand levels or TNF-␣ levels, supernatant was collected after 18 h of co-culture and an ELISA for soluble CD95 ligand or TNF-␤ (Bender MedSystems, Vienna, Austria) was performed as described above for IL-7. Levels of CD95 cell surface expression were detected on the T cells by FACS analysis employing a monoclonal anti-CD95 antibody (BD PharMingen). To assess the susceptibility to CD95-mediated apoptosis, pre-activated T lymphocytes were incubated with the anti-CD95 antibody anti-APO-1 IgG 3 at a final concentration of 1 g/ml 34 and apoptosis was assessed by measuring Annexin-V staining after 18 h of incubation.
For assessment of the pro-apoptotic capacity of supernatants from adenovirally transduced tumor cells, SAOS-2 cells were transduced with Ad-lacZ at a MOI of 100. After 3 days of incubation, supernatants from transduced or non-infected SAOS-2 cells were harvested and added to PBMC primarily stimulated in the presence of plastic bound anti-CD3 antibody (mouse IgG2a) (Orthoclone OKT 3; Janssen-Cilag, Neuss, Germany). Alternatively, supernatants were added to PBMC during restimulation with anti-CD3 antibody on day 6 after the initial activation. Apoptosis was measured at 18 h of primary or restimulation as described above.
Measurement of T cell cytotoxicity
For detection of cytotoxic T cell function, non-irradiated tumor cells were labeled with radioactive 51 chromium ( 51 Cr) (1 mCi/ml) (NEN, Life Science Products, Zaventem, Belgium, USA) for 1.5 h. Subsequently, tumor cells were added to the pre-activated T-effector cells at effector-target ratios (E:T) ranging from 50:1 to 1.6:1. After 4 h of co-culture in 96-well V-bottom plates, cytotoxic T cell activity was assessed by measuring radioactivity in culture supernatants with a scintillation counter (Topcount, Packard, Meriden, CT, USA). Specific lysis was calculated as described. 20 
Statistics
All experiments were performed at least three times. Results are expressed as means ± standard deviation (s.d.). Comparison between different stimulatory conditions was done by evaluating values from individual experiments employing the Wilcoxon test for paired samples.
